




C E R V O S  
M E D I C A L

# Advancing Clinical Outcomes through Enhanced Bone Marrow Aspiration:

The Impact of Marrow Cellution Technology




### **Biological characteristics of bone marrow and peripheral blood**

Bone marrow, the target biologic of bone marrow aspirate, resides within the spongy tissue encased by trabecular bone. Peripheral blood, which circulates through our body, is not the intended target of marrow aspiration, yet fills the space created by the aspiration canula.


Therefore, during the aspiration process, peripheral blood can fill the spaces within the marrow. This occurs due to the physical disruption caused by the aspiration needle, which creates a pathway through the bone and damages the spongy tissue's capillary network.

The primary goal during marrow aspiration is to extract the marrow fluid (BMA) from within this spongy tissue, avoiding the peripheral blood that exists outside this framework. Achieving this requires a greater suction force to be applied directly to the spongy marrow with less suction force applied to the peripheral fluid outside of the spongy marrow.

To obtain a marrow sample with improved cellular content, it's crucial to ensure that the syringe's suction is focused through the needle's apertures that are in immediate contact with the spongy marrow tissue. Once the aspiration process disrupts the capillary network within a specific area, causing peripheral blood to seep in, the needle must be moved to a new, undisturbed marrow site to continue the aspiration effectively. (5)




### ***Physical characteristics of bone marrow and peripheral blood***




Despite their similarities, peripheral blood and bone marrow exhibit distinct physical characteristics. Bone marrow's physical location within the spongy substrate and its greater viscosity necessitates greater shear force for fluid flow movement to extract it from the dense spongy tissue. Marrow houses unique cell lineages absent in peripheral blood, features a significantly higher ratio of nucleated to total cells, and is organized into specialized geographic niches (5,6). Among these, the endosteal surface – lining the hard inner cortical surface – represents the location where the oxygen tension is lowest and the stem-like quality of the cells is greatest. This highly protected area harbors the most primitive, stem-like cells, underscoring the rich stem cell content of bone marrow as opposed to the relative scarcity in peripheral blood (1,2,3,4).

### ***Mechanical considerations of marrow aspiration***



The rigid structure of the bone cavity can trap pressure built-up by inflammation due to the insertion of the cannula (7). As the needle penetrates further into the bone, friction against the outer cannula increases from two primary sources: the cortical bone at the entry point and the inflamed, swollen tissue within the medullary space. This friction heightens the risk of the cannula becoming stuck, particularly as it is inserted deeper.






*Low progenitor cell concentration*

### **Traditional bone marrow cannula design**


The design of a traditional bone marrow aspiration cannula features a two-component system: a hollow outer cannula and a sharp, inner stylet designed to fit snugly within it. Both the cannula and the stylet are affixed to their respective handles. This assembly allows for the separation of the components to reveal a luer hub integrated into the cannula's handle.

In practice, the combined needle, comprising both the cannula and the stylet, is inserted through the cortical bone to access the medullary cavity. Following insertion, the stylet is withdrawn, allowing for the attachment of a syringe to the cannula's luer hub. This setup facilitates the aspiration of bone marrow.



### **Limitations of the traditional bone marrow cannula**

**Risk of Lodging:** The deeper the needle penetrates the medullary cavity, the more friction it encounters, increasing the risk of the cannula becoming lodged. Therefore, it's generally advised against inserting these needles too deeply into the bone to mitigate this risk.



**Peripheral Blood Contamination:** Each area within the marrow has a limited cell and tissue capacity. Once the available material from a location is depleted, peripheral blood invades the space, leading to contamination. The risk of cannula lodging restricts access to diverse marrow regions. Upon insertion of a traditional cannula and removal of the stylet, the cannula's end becomes open, establishing fluid communication with the luer (1-5). Although side fenestrations on the cannula may open post-stylet removal, the primary suction pressure from the syringe connected to the luer targets the cannula's open distal end. This area, near the divot left by the removed stylet, is prone to filling with peripheral blood, characterized by its lower viscosity and shear stress, facilitating easier flow compared to marrow within the spongy structure. The syringe's maximal pressure point, near the open cannula end, aligns with this area of greater flow capacity peripheral blood, thus leading to peripheral blood contamination in the aspirate.


Attempting to reposition the cannula by retracting the needle aggravates the issue as the created channel fills with peripheral blood, situated close to the cannula's main opening. Efforts to target new locations by reinserting the stylet and moving forward do not significantly improve outcomes due to the bleeding into the site that occurs from the additional time required to accomplish the protocol, and the limited insertion depth to prevent lodging, often leaving new sites too close to previous ones for an enhanced cell yield. Various approaches with a traditional cannula—such as aspirating from a single point, repositioning within the marrow, or advancing to new areas—have proven ineffective (4,8,9,10). Consequently, the less favored solution involves creating multiple cortical punctures to extract minimal aspirate volumes, a method frequently impractical for clinical applications.



### **Marrow Cellution™ Technology**

Marrow Cellution™ technology innovatively addresses the challenges posed by traditional bone marrow aspiration techniques. This system is distinguished by three key design features:

1. **Blunt stylet:** After initial entry into the medullary space, a blunt stylet replaces the traditional sharp stylet to prevent the risk of the sharp stylet exiting the space during deeper insertion, going from proximal to distal.
2. **Mechanical precision:** A unique threaded mechanical element facilitates precise and controlled movement of the cannula. This modification is crucial for relocating the cannula to unexplored marrow regions, effectively broadening the scope of accessible areas for aspiration.
3. **Dedicated Aspiration Cannula:** Post stylet removal, a specialized aspiration cannula is introduced coaxially through the primary introducer cannula. This secondary cannula is designed to seal the end lumen, directing the aspiration process exclusively through side apertures. This design ensures that the aspirate is predominantly sourced from the marrow, minimizing peripheral blood contamination by orienting fluid flow towards the bone's inner endosteal surface.




By integrating these innovative elements, Marrow Cellution directly counters the traditional cannula's drawbacks, offering a more effective and efficient means of bone marrow aspiration that enhances the quality and purity of the harvested material.



**Comparative Stem Cell Content:**

In a series of five distinct head-to-head studies, Marrow Cellution aspirate was consistently found to contain a higher concentration of stem cells than aspirates processed by conventional centrifugation techniques. Notably, in two of these comparisons, the biological samples from the Marrow Cellution group displayed superior “stem-like” qualities, such as markers indicative of small embryonic-type cells and larger colony-forming unit sizes, underscoring the enriched stem cell profile of Marrow Cellution aspirates (23,24,25,26,27).



**Vascular Disorders Studies:**

Marrow Cellution’s efficacy was further demonstrated in two clinical studies focused on vascular disorders, where the Marrow Cellution group experienced significantly better outcomes than those treated with centrifuged samples, highlighting the therapeutic potential of Marrow Cellution-derived aspirates in vascular health (26,27).



“ Cellular and Clinical Analyses of Autologous Bone Marrow Aspirate Injectate for Knee Osteoarthritis: A Pilot Study  
**Marrow Cellution delivers a significantly higher cell count..**  
- G. Lutz, MD ”


**Comparison with Autograft:** When evaluated against the gold standard of autografts in orthopedics, Marrow Cellution’s performance was impressive. Analysis of 37 samples showed that Marrow Cellution’s osteoprogenitor and nucleated cell counts were comparable, if not superior, to those of autograft samples, indicating its robust regenerative capacity (24,28,29,30,31).

**Supportive Literature:** The efficacy and potential of Marrow Cellution technology are further corroborated by over 17 journal articles. These publications report positive outcomes, both clinical and cellular, derived from the use of Marrow Cellution technology, contributing to a growing body of evidence supporting its effectiveness in various therapeutic contexts (23,25,27,32-45).




“  
*Patients treated with BMA have superior changes in Quick-DASH & EQ-5D-5L pain and health scores (12-month post injection) when compared to patients treated with cortisone.*  
 - T. Dwyer, MD  
 ”

**ACL Tear Marrow Cellution: RSI**



Torn ACL from skiing accident. Acute injury.  
 Patient reports no pain that correlates to structural change in the MRI

Tim Dwyer et al. Injection of Bone Marrow Aspirate for Glenohumeral Joint Osteoarthritis: A Pilot Randomized Control Trial; Dwyer et al. Arthrosc Sports Med Rehabil 2021 Oct; 3(5): e1431–e1440



“  
 Autologous Bone Marrow Injections for Patients with Moderate Osteoarthritis of the Hip Joint.  
***BMA injection can provide long-term pain relief and functional restoration (as much as 6 to 12 months) for patients with hip osteoarthritis.***  
 - J.R Singh, MD  
 ”







The effectiveness of any medical device is significantly influenced by the user's expertise and the application of proper techniques.

In the context of Marrow Cellution, several practices have been identified that enhance outcomes:

- Utilizing a **10 mL syringe** for aspiration ensures optimal control and precision.
- Employing a **snap-back plunger technique** enhances the consistency and quality of the aspirate.
- Limiting the volume of aspiration to **no more than 1 mL per cm of targeted marrow area** helps maintain the integrity and concentration of the cell population.
- Carefully **orienting the side apertures towards the bone's inner surface (the inner table)** optimizes the collection of high-quality marrow while minimizing peripheral blood dilution.

Adhering to these guidelines has been demonstrated to improve cell counts in aspirates, underscoring the critical role of technique and training in maximizing the therapeutic potential of marrow aspiration. (30)





### ***A Commonsense Approach***

Minimizing intervention with biological materials often enhances their efficacy. Stem cells, known for their dynamic nature and prolificacy during division cycles, exemplify this principle. Prior to division, cells accumulate nucleic mass, resulting in a density surpassing that of cells typically isolated in the buffy coat layer. Crucially, many of these actively cycling cells are inadvertently discarded during centrifugation, along with the red cell layer, rather than being captured. Given that an estimated 45% of stem cells are in a state of division at any time, this biologic reality partly accounts for the low yield of stem cells retained from larger aspirates using centrifugation methods (9, 46, 47, 48). This inefficiency is a key reason hematologists/oncologists opt not to centrifuge bone marrow aspirates intended for transplant.

Cervos' offerings encompass a comprehensive suite of regenerative solutions. This diverse product range is designed to provide clinicians with the flexibility to combine different biologics and delivery tools to tailor treatment approaches specific to the unique needs of each patient.

**PRP (Platelet-Rich Plasma):** Our advanced PRP system is engineered to maximize the concentration and viability of platelets, harnessing their growth factors and healing properties for a wide range of therapeutic applications. This system ensures a high-dose PRP preparation. Clinical outcomes are linked to dose.



**Adipose:** Our adipose system facilitates the efficient harvesting and processing of adipose tissue. The system includes a built-in micronizing screen, and comes with disposable infiltration and aspiration cannulas. This technology supports treatments in regenerative medicine, cosmetic and reconstructive surgery, and chronic wound management.

**Bone Dowel Harvesting:** Addressing the need for structural support in various orthopedic and spinal procedures, our bone dowel harvesting tools are engineered for the safe and efficient extraction of bone dowels. This addition complements our regenerative therapy solutions, offering a solid framework for cellular integration and bone repair.



**Delivery Tools:** To ensure precise and effective application of biologic therapies within the medullary space, Cervos offers intraosseous access cannulas. These instruments enable clinicians to accurately target treatment areas within bone.

Each component of the Cervos product family is the result of extensive R&D and physician input aimed at providing healthcare professionals with state-of-the-art tools to improve patient outcomes.

By offering a range of solutions, Cervos empowers clinicians to customize regenerative therapies based on the patient's specific condition, promoting personalized and effective treatment strategies.



# Bibliography

---

1. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. *J Bone Joint Surg Am* 1997;79:1699-709.
  2. Batinic D, Marusic M, Pavletic Z, et al. Relationship between differing volumes of bone marrow aspirates and their cellular composition. *Bone marrow transplantation* 1990;6:103-7.
  3. Bacigalupo A, Tong J, Podesta M, et al. Bone marrow harvest for marrow transplantation: effect of multiple small (2 ml) or large (20 ml) aspirates. *Bone marrow transplantation* 1992;9:467-70.
  4. Hernigou P et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. *International orthopaedics* 2013;37:2279-87.
  5. Umet A et al. The Mechanical Environment of Bone Marrow: A Review *Annals of Biomedical Engineering*, Vol. 36, No. 12, December 2008 (Ó 2008) pp. 1978–1991 Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, West Lafayette, IN 47907-2032, USA
  6. Cordeiro E et al. The Bone Marrow Endosteal Niche: How Far from the Surface? *Journal of Cellular Biochemistry* 116:6–11, 2015
  7. Simkin, P.A. (2004). Bone Pain and Pressure in Osteoarthritic Joints. In *Osteoarthritic Joint Pain* (eds Novartis Foundation, D.J. Chadwick and J. Goode)
  8. McLain RF, Fleming JE, Boehm CA, Muschler GF. Aspiration of osteoprogenitor cells for augmenting spinal fusion: comparison of progenitor cell concentrations from the vertebral body and iliac crest. *J Bone Joint Surg Am* 2005;87:2655-61.
  9. Hegde V, Shonuga O, Ellis S, et al. A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration. *Journal of orthopaedic trauma* 2014;28:591-8.
  10. Jones et al; Rapid intraoperative concentration of mesenchymal stem cells from bone marrow aspirate *Spine Care*, Houston TX; Biomet Inc.
  11. Hernigou P et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. *International Orthopaedics*, 2014; 1811-1818
  12. Gan Y et al. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion *Biomaterials*, 2008, 3973-3982
  13. Hernigou et al. Treatment of Osteonecrosis with autologous bone marrow grafting *Clinical Orthopaedics and Related Research* number 405, pp 14-23
  14. Hernigou P, et al. Percutaneous Autologous Bone-Marrow Grafting for Nonunions –Influence of the Number and Concentration of Progenitor Cells *The Journal of Bone and Joint* Volume 87-A No 7 July 2000
  15. Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A. Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study. *Int Orthop*. 2020 Jul 2.
  16. Hernigou P, Delambre J, Quiennec S, Poignard A. Human bone marrow mesenchymal stem cell injection in subchondral lesions of knee osteoarthritis: a prospective randomized study versus contralateral arthroplasty at a mean fifteen year follow-up. *Int Orthop*. 2020 Apr 23. Epub ahead of print. PMID: 32322943
  17. Hernigou P, Auregan J, Dubory A, Flouzat-Lachaniette C, Chevallier N, Rouard H. Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee *International Orthopaedics*; 19 March 2018
  18. Dengshun D et al. Megakaryocyte-Bone Marrow Stromal Aggregates Demonstrate Increased Colony Formation and Alkaline Phosphatase Expression in *Vitro Tissue Engineering*; Vol 10 No. 5/6 2004(24)
  19. Menocal L et al. Role of whole bone marrow, whole bone marrow cultured cells, and mesenchymal stem cells in chronic wound healing *Stem Cell Research & Therapy* 2015 6:24
  20. Stellos et al. Platelet-Derived Stromal Cell-Derived Factor-1 Regulates Adhesion and Promotes Differentiation of Human CD34 + Cells to Endothelial Progenitor Cells *Circulation*, 117(2):206-215 2008
  21. Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 1 Year : A Prospective, Randomized Trial Adam W. Anz, \*† MD, et al. Investigation performed at the Andrews Research & Education Foundation, Gulf Breeze, Florida, USA *The Orthopaedic Journal of Sports Medicine*, 8(2)
  22. Navani A, Ambach M, Calodney A, et al. The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up. *Pain Physician*. 2024 Jan;27(1):E65-E77. PMID: 38285032.
  23. Isolation of clinically relevant concentrations of bone marrow mesenchymal stem cells without centrifugation Scarpone M, Kuebler D, Chambers A, et al. *J Transl Med*. 2019;17(1):10. Published 2019 Jan 5. doi:10.1186/s12967-018-1750-x
  24. White Paper: Comparison of two methods to Harvest vertebral body marrow aspirate: Novel lateral aspiration device compared to a standard cannula needle Bianco S et al
  25. Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction Bieri M, Said E, Antonini G, et al. *J Transl Med*. 2020;18(1):24. Published 2020 Jan 14. doi:10.1186/s12967-019-02195-w
  26. Preclinical Evaluation of Marrow Cellution Needle Compared to Traditional Aspiration and BioCUE Centrifugation System. Easley J, Sikes K, Bisazza K, Meyers M, Stewart H, Reves B. Preclinical Surgical Research Laboratory, Colorado State University. 2023.
  27. Caradonna E, Mormone E, Centritto EM, Mazzanti A, Papini S, Fanelli M, Petrella L, Petruzzello A, Farina MA, Farina E, Amato B, De Filippo CM, Vanoli E. Different methods of bone marrow harvesting influence cell characteristics and purity, affecting clinical outcomes. *JVS Vasc Sci*. 2023 Oct
  28. Lutz et al. Presented at The Orthobiologic Institute annual meeting in 2020.
  29. [White Paper] Marrow Cellution: The Impact of Volume on Related Cell Counts Using The MARROW CELLUTION™ Bone Marrow Aspiration System Scarpone M, Kuebler D.
-

30. [White Paper] Technique Matters: Small Draw, Diverse Geography, Precise Repositioning, Lateral Draws Only, Pace, and Syringe Plunger Yields Clinically Relevant CFU-f Counts Tortland P, Kuebler D. MC Publication / Study. 2020 Aug 01
31. George F. Muschler, MD The Cleveland Clinic Foundation, Cleveland, OH COMPARISON OF BONE MARROW ASPIRATION AND BONE CORE BIOPSY AS METHODS FOR HARVEST AND ASSAY OF HUMAN CONNECTIVE TISSUE PROGENITOR Paper #41 FIFTY-EIGHTH ANNUAL MEETING APRIL 3-7, 2006 Buenos Aires, Argentina
32. Bone marrow aspirate concentrate chondroplasty to delaying need for total knee arthroplasty: a retrospective review of a veteran cohort Pearl, A., Saleh, K., Korsog, D., & Mundt, J. *Regenerative Medicine*, 18(11), 833-838. 2023.
33. Hip Arthroscopy With Bone Marrow Aspirate Injection for Patients With Symptomatic Labral Tears and Early Degenerative Changes Shows Similar Improvement Compared With Patients Undergoing Hip Arthroscopy With Symptomatic Labral Tears Without Arthritis. Day, M. A., Hancock, K. J., Selley, R. S., Olsen, R., Ranawat, A. S., Nwachukwu, B. U., ... & Nawabi, D. H. *Arthroscopy: The Journal of Arthroscopic & Related Surgery*, 39(6), 1429-1437. 2023.
34. Osteo-core plasty: minimally invasive approach for subchondral pathologies Katarzyna Herman, Graeme P Whyte, Anna Montagna, Leandra Bizzoco, Nogah Shabshin, Dawid Szwedowski, Alberto Gobbi. *Journal of Cartilage & Joint Preservation*, Volume 3, Issue 1, 2023. 100101, ISSN 2667-2545
35. Intra-articular injection of bone marrow aspirate concentrate (BMAC) or adipose-derived stem cells (ADSCs) for knee osteoarthritis: a prospective comparative clinical trial Pintore, A., Notarfrancesco, D., Zara, A. et al. *J Orthop Surg Res* 18, 350. 2023. [Study]
36. Bone marrow aspirate injection for osteoarthritis of the hip; A pilot study Nicholas Tsitsilianos, Zainab Shirazi, Jessica Lu, Jaspal Ricky Singh. *Interventional Pain Medicine*. Volume 1, Issue 4, 2022. 100163, ISSN 2772-5944
37. Injection of Bone Marrow Aspirate for Glenohumeral Joint Osteoarthritis: A Pilot Randomized Control Trial Dwyer T, Hoit G, Lee A, et al. *Arthr. Sports Med Reh*. 2021;3(5):e1431-e1440.
38. Cellular and Clinical Analyses of Autologous Bone Marrow Aspirate Injectate for Knee Osteoarthritis: A Pilot Study Wells K, Klein M, Hurwitz N, et al. *PM R*. 2021;13(4):387-396. doi:10.1002/pmrj.12429
39. Autologous Minimally Invasive Cell-Based Therapy for Meniscal and Anterior Cruciate Ligament Regeneration Mahajan PV, Subramanian S, Parab SC, Mahajan S. *Case Rep Orthop*. 2021;2021:6614232. Published 2021 Jun 24. doi:10.1155/2021/6614232
40. Cellular and Clinical Analyses of Autologous Bone Marrow Aspirate Injectate for Knee Osteoarthritis: A Pilot Study Wells K, Klein M, Hurwitz N, et al. *PM R*. 2021;13(4):387-396. doi:10.1002/pmrj.12429 2020
41. Short-term outcomes after pure bone marrow aspirate injection for severe knee osteoarthritis: a case series Colberg RE, Jurado Vélez JA, Walsh KP, Fleisig G. *Regen Med*. 2020;15(7):1851-1859. doi:10.2217/rme-2019-0113
42. Positive early clinical outcomes of bone marrow aspirate concentrate for osteoarthritis using a novel fenestrated trocar Varady NH, Cate G, Barghi A, et al. *Knee*. 2020;27(5):1627-1634. doi:10.1016/j.knee.2020.08.018
43. Autologous Biologic Treatment with Fat, Bone Marrow Aspirate and Platelet Rich Plasma Is an Effective Alternative to Total Knee Arthroplasty for Patients with Moderate Knee Arthrosis Prodromos C, Finkle S. *Medicines (Basel)*. 2020;7(6):37. Published 2020 Jun 25. doi:10.3390/medicines7060037
44. Short-Term Efficacy of Using a Novel Low-Volume Bone Marrow Aspiration Technique to Treat Knee Osteoarthritis: A Retrospective Cohort Study Kuebler D, Schnee A, Moore L, et al. *Stem Cells Int*. 2022;2022:5394441. Published 2022 Nov 15. doi:10.1155/2022/5394441
45. Pure bone marrow aspirate injection for chronic greater trochanteric pain syndrome: a case report Henderson RG, Colberg RE. *Pain Manag*. 2018;8(4):271-275. doi:10.2217/pmt-2018-0008
46. Juopperi T et al. Isolation of bone marrow-derived stem cells using density-gradient separation. *Experimental hematology* 2007;35:335-41.
47. Bhartiya D et al. Very small embryonic-like stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous stem cell therapy. *Stem cells and development* 2012;21:1-6.
48. Ahmadbeigi N et al. The aggregate nature of human mesenchymal stromal cells in native bone marrow. *Cytotherapy* 2012;14:917-24.